![]() |
|
|
Vol. 53, Issue 3, 467-474, March 1998
Pharmacological Institutes and Drug Research and Development Group, We obtained a primary culture of prostatic cells through explantation
from patients with benign prostatic hyperplasia. Structural morphology,
immunohistochemical staining, and growth characteristics of these cells
demonstrate that they are consistent with the population of smooth
muscle cells (SMCs). We examined the influence of a nitric oxide donor,
sodium nitroprusside (SNP), on the regulation of human prostatic SMC
proliferation. SNP exhibited a concentration-dependent (0.1-10
µM) inhibition of fetal calf serum-induced proliferation in human prostatic SMCs. In addition, growth-inhibitory responses to
8-bromo-cGMP (1-30 µM) were observed. However, the
responses to SNP were significantly diminished by the presence of
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (3 µM; a selective guanylate cyclase inhibitor).
Furthermore, SNP induced an increased concentration-dependent
accumulation of intracellular cGMP in human prostatic SMCs. After 48-hr
period of deprivation of serum, cells were restimulated with serum to permit cell cycle progression. The addition of SNP (10 µM) at various times after the addition of serum to
serum-deprived cells showed maximal inhibition of cell proliferation
even when added 6 hr after the serum. This blocking effect of cell
cycle progression was lost gradually as the delay from serum to SNP
application increased from 6 to 18 hr. The membrane-associated protein
kinase C (PKC) activity was studied in human prostatic SMCs; results showed that fetal calf serum (10%, v/v) significantly increased membrane-associated PKC activity. SNP (10 µM), which had
little effect on basal kinase activity, completely abolished
serum-induced augmentation of PKC activity. Therefore, we suggest that
SNP mediates its antiproliferative effect by the inhibition of PKC
activity on human prostatic SMCs; furthermore, its antiproliferative
effect occurs at the early G1 phase of the cell cycle.
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics
This article has been cited by other articles:
![]() |
M. Schleicher and W. C. Sessa Are the Mechanisms for NO-Dependent Vascular Remodeling Different From Vasorelaxation In Vivo? Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1207 - 1208. [Full Text] [PDF] |
||||
![]() |
B. Zhu, S. Strada, and T. Stevens Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells Am J Physiol Lung Cell Mol Physiol, August 1, 2005; 289(2): L196 - L206. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. D'Andrea, Y. Qiu, D. Haynes-Johnson, S. Bhattacharjee, P. Kraft, and S. Lundeen Expression of PDE11A in Normal and Malignant Human Tissues J. Histochem. Cytochem., July 1, 2005; 53(7): 895 - 903. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-T. Huang, D.-M. Huang, J.-H. Guh, I-L. Chen, C.-C. Tzeng, and C.-M. Teng CIL-102 Interacts with Microtubule Polymerization and Causes Mitotic Arrest following Apoptosis in the Human Prostate Cancer PC-3 Cell Line J. Biol. Chem., January 28, 2005; 280(4): 2771 - 2779. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. HORTELANO, A. M. ALVAREZ, and L. BOSCÁ Nitric oxide induces tyrosine nitration and release of cytochrome c preceding an increase of mitochondrial transmembrane potential in macrophages FASEB J, December 1, 1999; 13(15): 2311 - 2317. [Abstract] [Full Text] |
||||
![]() |
K. Yuasa, J. Kotera, K. Fujishige, H. Michibata, T. Sasaki, and K. Omori Isolation and Characterization of Two Novel Phosphodiesterase PDE11A Variants Showing Unique Structure and Tissue-specific Expression J. Biol. Chem., September 29, 2000; 275(40): 31469 - 31479. [Abstract] [Full Text] [PDF] |
||||